Journal Mobile Options
Table of Contents
Vol. 46, No. 6, 2000
Issue release date: November–December 2000
Chemotherapy 2000;46:395–401
(DOI:10.1159/000007320)

In vitro Susceptibility of Candida dubliniensis to Current and New Antifungal Agents

Quindós G. · Carrillo-Muñoz A.J. · Arévalo M.P. · Salgado J. · Alonso-Vargas R. · Rodrigo J.M. · Ruesga M.T. · Valverde A. · Pemán J. · Cantón E. · Martín-Mazuelos E. · Pontón J.
aDepartamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidad del País Vasco, Bilbao, bDepartamento de Microbiología, ACIA, Barcelona, cCátedra de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad de La Laguna, La Laguna, Tenerife, dServicio de Microbiología Clínica, Hospital Universitario Valme, Seville, and eServicio de Microbiología, Hospital La Fe, Valencia, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Candida dubliniensis is a recently described Candida species closely related to Candida albicans, which has been associated with oral candidiasis in HIV-infected patients. Fluconazole-resistant strains of C. dubliniensis are easily obtained in vitro and this fact could be a complication if this resistance develops during treatment with this drug. Methods: In the present study, the in vitro antifungal susceptibilities of 36 C. dubliniensis clinical isolates and culture strains to current and new antifungal agents, such as amphotericin B (AMB), amphotericin B lipid complex (ABLC), amphotericin B colloidal dispersion (ABCD), 5-fluorocytosine (5FC), fluconazole (FLC), itraconazole (ITC), ketoconazole (KTC), liposomal amphoteri- cin B (LAMB), liposomal nystatin (LNYT), LY303366 (LY), SCH56592 (SCH), and voriconazole (VRC), were determined according to the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for yeasts. Results: Most isolates of C. dubliniensis were susceptible to both new and current antifungal drugs, with 75.9% isolates susceptible to KTC, 86.2% to FLC and to ITC, and ∼100% to the other antifungal agents tested. The cross-resistance phenotypes are detailed. Four isolates were resistant (MIC ≥64 μg/ml) to FLC. These 4 isolates were also resistant to KTC, and 3 of them were also resistant to ITC (MIC ≥1 μg/ml for both agents). However, these isolates were highly susceptible to 5FC and all polyene formulations (AMB, ABLC, ABCD, LAMB, and LNYT), triazole (SCH and VRC) and echinocandin (LY) antifungal agents. Conclusion: The new liposomal and lipidic formulations of AMB, LNYT, and the new triazoles and echinocandins may provide new alternatives to FLC for the treatment of infections by C. dubliniensis.

Copyright © 2000 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Gilfillan GD, Sullivan DJ, Haynes K, Parkinson T, Coleman DC, Gow NAR: Candida dubliniensis: Phylogeny and putative factors. Microbiology 1998;144:829–838.
  2. Sullivan D, Haynes K, Bille J, Boerlin P, Rodero L, Lloyd S, Henman M, Coleman D: Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J Clin Microbiol 1997;35:960–964.
  3. Sullivan D, Moran G, Donnelly S, Gee S, Pinjon E, McCartan B, Shanley DB, Coleman DC: Candida dubliniensis: An update. Rev Iberoam Micol 1999;16:72–76.
  4. Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, Coleman DC, Soll DR: In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999;37:870–872.
  5. Moran GP, Sullivan DJ, Henman MC, McCreary CE, Harrington BJ, Shanley DB, Coleman DC: Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 1997;41:617–623.
  6. Moran GP, Sanglard D, Donelly SM, Shanley DB, Sullivan DJ, Coleman DC: Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 1998;42:1819–1830.
  7. McGinnis MR: Laboratory Handbook of Medical Mycology. New York, Academic Press, 1980, pp 357–359.
  8. Bikandi J, San Millán R, Moragues MD, Cebas G, Coleman DC, Quindós G, Pontón J: Rapid identification of Candida dubliniensis by indirect immunofluorescence. J Clin Microbiol 1998;36:2428–2433.
  9. NCCLS: Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard. NCCLS document M27-A. Wayne, National Committee for Clinical Laboratory Standards. 1997.
  10. Wallace TL, López-Berenstein G: Nystatin and liposomal nystatin; in Yu VL, Merigan TC, Barriere S, White NJ (eds): Antimicrobial Therapy and Vaccines. Baltimore, Williams & Wilkins, 1998, pp 1185–1191.
  11. Ceballos Salobreña A, Gaitán Cepeda LA, Ruesga MT, Ceballos García L, Quindós G: Prevalencia de lesiones orales por Candida en una población con sida sometida a terapia antirretroviral altamente activa. Rev Iberoam Micol 1998;15:141–145.
  12. Odds FC, Van Nuffel L, Dams G: Prevalence of Candida dubliniensis in a yeast stock collection. J Clin Microbiol 1998;36:2869–2873.
  13. Canton E, Peman J, Carrillo-Muñoz A, Orero A, Ubeda P, Viudes A, Gobernado M: Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. J Clin Microbiol 1999;37:2197–2200.

    External Resources

  14. Kirkpatrick WR, Revankar SG, McAtee RK, Lopez-Ribot JL, Fothergill AW, McCarthy DI, Sanche SE, Cantu RA, Rinaldi MG, Patterson TF: Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing. J Clin Microbiol 1998;36:3007–3012.
  15. Stevens DA, Stevens JA: Cross-resistance phenotypes of fluconazole-resistant Candida species: Results with 655 clinical isolates with different methods. Diagn Microbiol Infect Dis 1996;26:145–148.

    External Resources

  16. Jabra-Rizk MA, Baqui AAMA, Kelley JI, Falkler WA Jr, Merz WG, Meiller TF: Identification of Candida dubliniensis in a prospective study of patients in the United States. J Clin Microbiol 1999;37:321–326.
  17. Carrillo-Muñoz AJ, Quindós G, Tur C, Ruesga MT, Miranda Y, del Valle O, Cossum PA, Wallace TL: In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother 1999;44:397–401.

    External Resources

  18. Chávez M, Bernal S, Martín Mazuelos E, Valverde A, Gutiérrez MJ, Quindós G: In-vitro activity of voriconazole and LY-303366 against oral Candida isolates from HIV-infected patients. J Antimicrob Chemother 1999;44:44: 689–691.
  19. Espinel-Ingroff A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY 303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950–2956.
  20. Andriole VT: Current and future antifungal therapy: New targets for antifungal agents. J Antimicrob Chemother 1999;44:151–162.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50